ReShape Lifesciences Inc. (RSLS) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In USD
Address
1001 Calle Amanecer
San Clemente, CA 92673
United States of America (the)
Phone
949 429 6680
Sector
Healthcare
Industry
Medical - Devices
Employees
17
First IPO Date
October 06, 2016
| Name | Title | Pay | Year Born |
| Paul F. Hickey | Chief Executive Officer, President & Director | 323,984 | 1965 |
| Dan W. Gladney | Executive Chair | 121,078 | 1953 |
| Thomas Stankovich | Senior Vice President & Chief Financial Officer | 148,698 | 1961 |
| Naqeeb A. Ansari | Senior Vice President of Global Commercial Operations | 327,464 | 1961 |
| Dov Gal | Vice President of Regulatory Clinical Quality & Compliance Officer | 0 | N/A |
| Al Diaz | Vice President of Operations and R&D | 0 | N/A |
Founded in 2002 and based in San Clemente, California, ReShape Lifesciences Inc. operates as a medical device company dedicated to addressing obesity and metabolic diseases. The company's market extends throughout the United States, Australia, Europe, and globally. Its diverse product lineup features the Lap-Band System, a minimally invasive, long-term solution for severe obesity that offers an alternative to more extensive surgical interventions like gastric bypass or sleeve gastrectomy. Under development is the ReShape Vest system, an investigational, minimally invasive device that is laparoscopically implanted around the stomach to assist obese and morbidly obese patients in losing weight, without cutting or permanently removing parts of the stomach or bypassing any section of the gastrointestinal tract. ReShape also supports patients through the ReShapeCare virtual health coaching program, a telehealth service aimed at promoting healthy lifestyle adjustments for individuals undergoing medically supervised weight management. Additionally, the company is conducting preclinical development for ReShape Diabetes Bloc-Stim Neuromodulation, a technology intended for the treatment of type 2 diabetes mellitus. Among its offerings is the Obalon Balloon System, a swallowable capsule used to monitor and display the balloon's exact position during its placement. The company, initially incorporated as EnteroMedics Inc., changed its name to ReShape Lifesciences Inc. in 2017.